WO2005076001A3 - A polypeptide derived from gp41, a vaccine composition comprising said polypeptide, and uses for treating an infection by an hiv virus in an individual - Google Patents

A polypeptide derived from gp41, a vaccine composition comprising said polypeptide, and uses for treating an infection by an hiv virus in an individual Download PDF

Info

Publication number
WO2005076001A3
WO2005076001A3 PCT/EP2005/001395 EP2005001395W WO2005076001A3 WO 2005076001 A3 WO2005076001 A3 WO 2005076001A3 EP 2005001395 W EP2005001395 W EP 2005001395W WO 2005076001 A3 WO2005076001 A3 WO 2005076001A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
infection
individual
treating
vaccine composition
Prior art date
Application number
PCT/EP2005/001395
Other languages
French (fr)
Other versions
WO2005076001A2 (en
Inventor
Vincent Vieillard
Patrice Debre
Original Assignee
Inst Nat Sante Rech Med
Vincent Vieillard
Patrice Debre
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2004/001106 external-priority patent/WO2004070385A1/en
Application filed by Inst Nat Sante Rech Med, Vincent Vieillard, Patrice Debre filed Critical Inst Nat Sante Rech Med
Priority to EP05715302A priority Critical patent/EP1714153A2/en
Priority to CN2005800108157A priority patent/CN1954217B/en
Priority to US10/588,633 priority patent/US20070092525A1/en
Priority to CA2558733A priority patent/CA2558733C/en
Publication of WO2005076001A2 publication Critical patent/WO2005076001A2/en
Publication of WO2005076001A3 publication Critical patent/WO2005076001A3/en
Priority to US12/362,124 priority patent/US20090136533A1/en
Priority to US14/286,467 priority patent/US20140335119A1/en
Priority to US15/360,175 priority patent/US20170128564A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to the field of the in vitro diagnosis of the progression status of an infection of an individual with a virus belonging to the family of the Human Immunodeficiency Viruses (HIV) as well as with the therapeutical treatment of this infectious disease. The invention also relates to immunological compounds and vaccine compositions comprising a polypeptide derived from gp41.
PCT/EP2005/001395 2003-02-06 2005-02-07 A polypeptide derived from gp41, a vaccine composition comprising said polypeptide, and uses for treating an infection by an hiv virus in an individual WO2005076001A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP05715302A EP1714153A2 (en) 2004-02-06 2005-02-07 A polypeptide derived from gp41, a vaccine composition comprising said polypeptide, and uses for treating an infection by an hiv virus in an individual
CN2005800108157A CN1954217B (en) 2004-02-06 2005-02-07 A polypeptide derived from gp41, a vaccine composition comprising said polypeptide, and uses for treating an infection by an HIV virus in an individual
US10/588,633 US20070092525A1 (en) 2005-02-07 2005-02-07 Polypeptide derived from gp41, a vaccine composition comprising said polypeptide, and uses for treating an infection by an hiv virus in an individual
CA2558733A CA2558733C (en) 2004-02-06 2005-02-07 A polypeptide derived from gp41, a vaccine composition comprising said polypeptide, and uses for treating an infection by an hiv virus in an individual
US12/362,124 US20090136533A1 (en) 2003-02-06 2009-01-29 POLYPEPTIDE DERIVED FROM gp41, A VACCINE COMPOSITION COMPRISING SAID POLYPEPTIDE, AND USES FOR TREATING AN INFECTION BY AN HIV VIRUS IN AN INDIVIDUAL
US14/286,467 US20140335119A1 (en) 2004-02-06 2014-05-23 POLYPEPTIDE DERIVED FROM gp41, A VACCINE COMPOSITION COMPRISING SAID POLYPEPTIDE, AND USES FOR TREATING AN INFECTION BY AN HIV VIRUS IN AN INDIVIDUAL
US15/360,175 US20170128564A1 (en) 2003-02-06 2016-11-23 POLYPEPTIDE DERIVED FROM gp41, A VACCINE COMPOSITION COMPRISING SAID POLYPEPTIDE, AND USES FOR TREATING AN INFECTION BY AN HIV VIRUS IN AN INDIVIDUAL

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2004/001106 WO2004070385A1 (en) 2003-02-06 2004-02-06 A method for the in vitro assessment of the progression status of an infection by an hiv virus in an individual
EPPCT/EP2004/01106 2004-02-06

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/001106 Continuation WO2004070385A1 (en) 2003-02-06 2004-02-06 A method for the in vitro assessment of the progression status of an infection by an hiv virus in an individual

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/588,633 A-371-Of-International US20070092525A1 (en) 2003-02-06 2005-02-07 Polypeptide derived from gp41, a vaccine composition comprising said polypeptide, and uses for treating an infection by an hiv virus in an individual
US12/362,124 Continuation US20090136533A1 (en) 2003-02-06 2009-01-29 POLYPEPTIDE DERIVED FROM gp41, A VACCINE COMPOSITION COMPRISING SAID POLYPEPTIDE, AND USES FOR TREATING AN INFECTION BY AN HIV VIRUS IN AN INDIVIDUAL

Publications (2)

Publication Number Publication Date
WO2005076001A2 WO2005076001A2 (en) 2005-08-18
WO2005076001A3 true WO2005076001A3 (en) 2005-11-24

Family

ID=34833870

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/001395 WO2005076001A2 (en) 2003-02-06 2005-02-07 A polypeptide derived from gp41, a vaccine composition comprising said polypeptide, and uses for treating an infection by an hiv virus in an individual

Country Status (3)

Country Link
CN (1) CN1954217B (en)
CA (1) CA2558733C (en)
WO (1) WO2005076001A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010040853A1 (en) * 2008-10-10 2010-04-15 INSERM (Institut National de la Santé et de la Recherche Médicale) A method for the screening of candidate substances active against the infection of a subject by a hiv virus and kits for performing the said method
EP2213299B1 (en) 2009-01-29 2015-09-09 Michel Vandevelde Virus-based vaccine composition having a protein with zinc finger pattern(s), method of preparing and using same
CN102532280A (en) * 2010-12-08 2012-07-04 吉林大学 HIV (human immunodeficiency virus) immunogen and preparation thereof
WO2016184963A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
WO2016184962A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
WO2018065628A2 (en) 2016-10-07 2018-04-12 Enterome Microbiota sequence variants of tumor-related antigenic epitopes
AU2017339577B2 (en) * 2016-10-07 2021-12-02 Enterome S.A. Immunogenic compounds for cancer therapy
CN114397460B (en) * 2021-12-09 2022-11-11 华南理工大学 Biomarker storage solution and biomarker reagent

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002008287A2 (en) * 2000-07-20 2002-01-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Nk cells activating receptors and their therapeutic and diagnostic uses
WO2002053587A2 (en) * 2001-01-05 2002-07-11 Aventis Pasteur Polypeptide inducing hiv-neutralising antibodies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1108820C (en) * 1999-11-12 2003-05-21 清华大学 Preparation of epitope vaccine with single monoepitope or multiple monoepitope duplication
CN1339320A (en) * 2000-08-18 2002-03-13 清华大学 AIDS vacuum and its preparing method and use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002008287A2 (en) * 2000-07-20 2002-01-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Nk cells activating receptors and their therapeutic and diagnostic uses
WO2002053587A2 (en) * 2001-01-05 2002-07-11 Aventis Pasteur Polypeptide inducing hiv-neutralising antibodies

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHEN C-H ET AL: "MONOCLONAL ANTIBODIES THAT BIND TO THE CORE OF FUSION-ACTIVE GLYCOPROTEIN 41", AIDS RESEARCH AND HUMAN RETROVIRUSES, MARY ANN LIEBERT, US, vol. 16, no. 18, 10 December 2000 (2000-12-10), pages 2037 - 2041, XP002172035, ISSN: 0889-2229 *
MWAENGO D M ET AL: "Molecular cloning and characterization of viruses isolated from chimpanzees with pathogenic human immunodeficiency virus type 1 infections", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 72, no. 11, November 1998 (1998-11-01), pages 8976 - 8987, XP002283276, ISSN: 0022-538X *
RUY J-R ET AL: "DEVELOPMENT OF AN IN VITRO ASSAY SYSTEM FOR SCREENING OF GP41 INHIBITORY COMPOUNDS", MOLECULES AND CELLS, SEOUL, KR, vol. 8, no. 6, 31 December 1998 (1998-12-31), pages 717 - 723, XP001007287, ISSN: 1016-8478 *
See also references of EP1714153A2 *
VIEILLARD VINCENT ET AL: "NK cytotoxicity against CD4+ T cells during HIV-1 infection: A gp41 peptide induces the expression of an NKp44 ligand.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2 AUG 2005, vol. 102, no. 31, 2 August 2005 (2005-08-02), pages 10981 - 10986, XP002341851, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
CA2558733A1 (en) 2005-08-18
CA2558733C (en) 2016-04-19
CN1954217A (en) 2007-04-25
CN1954217B (en) 2013-05-08
WO2005076001A2 (en) 2005-08-18

Similar Documents

Publication Publication Date Title
WO2005076001A3 (en) A polypeptide derived from gp41, a vaccine composition comprising said polypeptide, and uses for treating an infection by an hiv virus in an individual
CA2556829C (en) Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production
WO2007041487A3 (en) Viral peptides and their use to inhibit viral infections against viruses of the flaviridae family
WO2009094191A3 (en) Methods of treating viral infections
EP3266464A3 (en) Yeast-based therapeutic for chronic hepatitis b infection
WO2004071426A3 (en) Compounds for the treatment of viral infection
MX2010001733A (en) Imidazopyrazine compounds.
WO2007057763A3 (en) Nitric oxide as an anti-viral agent, vaccine and vaccine adjuvant
IL182315A0 (en) 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection
EA200900156A1 (en) Pyridazine compound (VARIANTS), METHOD FOR ITS PREPARATION (VARIANTS), METHOD FOR TREATMENT OR PREVENTION OF VIRAL INFECTION WITH HEPATITIS C USING IT, compositions and medicaments based on its
WO2007041632A3 (en) Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection
WO2006110831A3 (en) Method of inducing neutralizing antibodies to human immunodeficiency virus
EP2568289A3 (en) Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
WO2005028496A3 (en) Vaccine for treatment and prevention of herpes simplex virus infection
EP2495252A3 (en) Soluble forms of hendra and nipah virus G glycoprotein
EA201491969A1 (en) IMMUNOGENIC COMPOUNDS INCLUDING HIV PEPTIDE GP41, ASSOCIATED WITH CRM197 CARRIER MEDICINE
WO2006045616A3 (en) β-L-N4-HYDROXYCYTOSINE DEOXYNUCLEOSIDES AND THEIR USE AS PHARMACEUTICAL AGENTS IN THE PROPHYLAXIS OR THERAPY OF VIRAL DISEASES
JP2008500963A5 (en)
WO2007065007A3 (en) Treatment of viral infections
WO2010041241A3 (en) Hiv-1 integrase derived stimulatory peptides interfering with integrase - rev protein binding
WO2007098247A3 (en) Substituted taraxastanes useful for treating viral infections
WO2008064072A3 (en) Anti-tsg101 antibodies and their uses for treatment of viral infections
GB2463584A (en) Carbohydrate-lipid constructs and their use in preventing or treating viral infection
CA2519012C (en) A method for the in vitro assessment of the progression status of an infection by an hiv virus in an individual
WO2009126308A3 (en) Compositions and methods for vaccine and virus production

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2005715302

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007092525

Country of ref document: US

Ref document number: 10588633

Country of ref document: US

Ref document number: 2558733

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 200580010815.7

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005715302

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10588633

Country of ref document: US